Form 4: AGIOS Director Scadden Exercises, Sells Shares

AGIOS Pharmaceuticals Director David Scadden exercised stock options and immediately sold an equal number of shares under a pre-arranged 10b5-1 trading plan.

Summary

• Director David Scadden exercised 200 stock options for Agios Pharmaceuticals common stock at an exercise price of $18.09 per share.
• Concurrently, Scadden sold 200 shares of Agios common stock at a price of $43.84 per share.
• These transactions were executed on November 12, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.
• Following these transactions, Scadden directly owns 17,603 shares of common stock and 26,907 stock options.

Sentiment

Score: 7

Explanation: The transaction is a routine insider sale under a 10b5-1 plan, indicating a director monetizing vested options. The sale price significantly exceeds the exercise price, which is positive for the director, but the transaction itself is neutral for the company's operational outlook.

Positives

• Director Scadden realized a profit by selling shares at $43.84 after exercising options at $18.09.
• The transactions were conducted under a Rule 10b5-1 trading plan, indicating pre-planning and reducing concerns about opportunistic insider trading.

Negatives

• No direct negatives are apparent from this routine insider transaction.

Risks

• NA

Future Outlook

NA

Management Comments

• NA

Industry Context

NA

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: The transaction represents a routine monetization of vested equity compensation by a director, which is a common occurrence and generally has a neutral impact on the company's valuation or operational prospects.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• NA

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where a director exercised vested stock options and immediately sold the acquired shares under a pre-arranged 10b5-1 plan. While the director realized a profit, this type of transaction is common for executive compensation and liquidity and does not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing. Investors should continue to hold and monitor the company's operational performance and broader market trends.

Keywords

AGIOS Pharmaceuticals, AGIO, Form 4, Insider Transaction, Stock Options, Rule 10b5-1, Director Transaction, Equity Sale, Beneficial Ownership